Representative Thomas H. Kean, Jr. (R-New Jersey) recently sold shares of Stryker Co. (NYSE:SYK). In a filing disclosed on March 14th, the Representative disclosed that they had sold between $15,001 and $50,000 in Stryker stock on February 26th. The trade occurred in the Representative’s “STATE STREET BANK & TRUST CO.” account.
Representative Thomas H. Kean, Jr. also recently made the following trade(s):
- Purchased $1,001 – $15,000 in shares of Amazon.com (NASDAQ:AMZN) on 2/26/2025.
- Sold $1,001 – $15,000 in shares of Magnera (NYSE:MAGN) on 2/12/2025.
- Purchased $1,001 – $15,000 in shares of Microsoft (NASDAQ:MSFT) on 1/31/2025.
- Purchased $1,001 – $15,000 in shares of Amazon.com (NASDAQ:AMZN) on 1/16/2025.
- Purchased $1,001 – $15,000 in shares of Crown (NYSE:CCK) on 1/7/2025.
- Purchased $1,001 – $15,000 in shares of Canadian Pacific Kansas City (NYSE:CP) on 12/27/2024.
- Purchased $1,001 – $15,000 in shares of Pernod Ricard (OTC:PRNDY) on 12/27/2024.
- Sold $1,001 – $15,000 in shares of Alphabet (NASDAQ:GOOG) on 12/19/2024.
- Sold $1,001 – $15,000 in shares of Franklin Resources (NYSE:BEN) on 12/16/2024.
- Purchased $1,001 – $15,000 in shares of Prologis (NYSE:PLD) on 12/16/2024.
Stryker Stock Up 1.7 %
Shares of NYSE SYK opened at $369.96 on Friday. The firm has a market capitalization of $141.17 billion, a PE ratio of 47.68, a price-to-earnings-growth ratio of 2.93 and a beta of 0.95. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59. Stryker Co. has a 1 year low of $314.93 and a 1 year high of $406.19. The firm’s 50-day moving average is $383.04 and its 200-day moving average is $373.48.
Stryker Announces Dividend
The firm also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be paid a $0.84 dividend. This represents a $3.36 annualized dividend and a dividend yield of 0.91%. The ex-dividend date of this dividend is Monday, March 31st. Stryker’s dividend payout ratio (DPR) is presently 43.30%.
Wall Street Analyst Weigh In
Several research analysts recently weighed in on the stock. The Goldman Sachs Group set a $422.00 price objective on shares of Stryker in a research note on Tuesday, March 4th. Wells Fargo & Company lifted their price objective on shares of Stryker from $427.00 to $435.00 and gave the stock an “overweight” rating in a research note on Wednesday, January 29th. Canaccord Genuity Group lifted their price objective on shares of Stryker from $420.00 to $435.00 and gave the stock a “buy” rating in a research note on Wednesday, January 29th. Argus set a $450.00 price target on shares of Stryker in a research note on Monday, February 3rd. Finally, Truist Financial lifted their price target on shares of Stryker from $409.00 to $413.00 and gave the company a “hold” rating in a research note on Thursday, January 30th. Five analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company. According to data from MarketBeat.com, Stryker has a consensus rating of “Moderate Buy” and an average price target of $421.90.
Check Out Our Latest Stock Report on Stryker
Hedge Funds Weigh In On Stryker
Institutional investors have recently added to or reduced their stakes in the company. Kohmann Bosshard Financial Services LLC acquired a new position in Stryker during the fourth quarter worth $25,000. Capital A Wealth Management LLC acquired a new position in Stryker during the fourth quarter worth $26,000. Dunhill Financial LLC increased its holdings in Stryker by 94.9% during the third quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company’s stock worth $27,000 after buying an additional 37 shares during the last quarter. Rakuten Securities Inc. increased its holdings in Stryker by 618.2% during the fourth quarter. Rakuten Securities Inc. now owns 79 shares of the medical technology company’s stock worth $28,000 after buying an additional 68 shares during the last quarter. Finally, Centricity Wealth Management LLC acquired a new position in Stryker during the fourth quarter worth $30,000. 77.09% of the stock is currently owned by institutional investors and hedge funds.
Insider Buying and Selling
In other Stryker news, Director Allan C. Golston sold 2,458 shares of Stryker stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total transaction of $941,586.06. Following the completion of the transaction, the director now directly owns 14,895 shares of the company’s stock, valued at $5,705,827.65. The trade was a 14.16 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Ronda E. Stryker sold 201,392 shares of Stryker stock in a transaction on Friday, January 31st. The stock was sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the transaction, the director now directly owns 3,642,075 shares of the company’s stock, valued at approximately $1,428,567,498. This trade represents a 5.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.90% of the stock is owned by corporate insiders.
About Representative Kean
Thomas Kean Jr. (Republican Party) is a member of the U.S. House, representing New Jersey’s 7th Congressional District. He assumed office on January 3, 2023. His current term ends on January 3, 2027.
Kean (Republican Party) is running for re-election to the U.S. House to represent New Jersey’s 7th Congressional District. He declared candidacy for the 2026 election.
Thomas Kean Jr. lives in Westfield, New Jersey. Kean earned a master’s degree from the Tufts University Fletcher School of Law and Diplomacy. His career experience includes working with the Environmental Protection Agency during the George H.W. Bush administration and as an advisor to former U.S. Representative Bob Franks, a firefighter, and an emergency medical technician. Kean has served as the vice president of a fire department.
About Stryker
Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.
Recommended Stories
- Five stocks we like better than Stryker
- Ride Out The Recession With These Dividend Kings
- Ignore Reports, Apple Won’t Install Starlink with iOS 18.3
- What Are the FAANG Stocks and Are They Good Investments?
- Casey’s Uptrend Remains Strong—New Highs on the Horizon
- How to Invest in Insurance Companies: A Guide
- Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.